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Abstract The main rationale for using biosimilar drugs is
for cost saving. The market development for biosimilar
drugs will therefore depend on the degree to which cost
saving measures are required by nations, medical insurers
and individuals and the absolute savings that could be
gained by switching from original drugs. This paper is
designed to discover the degree to which financial
constraints will drive future health spending and to discover
if legal or safety issues could impact on any trend. A
structured literature search was performed for papers and
documents to 27 August 2011. Where multiple sources of
data were available on a topic, data from papers and reports
by multinational or national bodies were used in preference
to data from regions or individual hospitals. Almost all
health systems face current significant cost pressures. The
twin driver of increasing cancer prevalence as populations
age and cancer medicine costs rising faster than inflation
places oncology as the most significant single cost problem.
For some countries, this is predicted to make medicine
unaffordable within a decade. Most developed countries
have planned to embrace biosimilar use as a cost-control
measure. Biosimilar introduction into the EU has already
forced prices down, both the price of biosimilar drugs and
competitive price reductions in originator drugs. Compound
annual growth rates of use have been predicted at 65.8%
per year. Most developed countries have planned to
embrace biosimilar use as a major cost-control measure.
Only legal blocks and safety concerns are likely to act
against this trend. For centralised healthcare systems, and
those with a strong tradition of generic medicine use,
biosimilar use will clearly rise with predictions of more
than 80% of prescriptions of some biologic drugs within
1 year of market entry in the USA. Delaying the
implementation of such programmes however risks a real
crisis in healthcare delivery for many countries and
hospitals that few can now afford.
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Background
The main rationale for using biosimilar drugs, rather than
the original version, is for cost saving. The market
development for biosimilar drugs will therefore depend on
the degree to which cost-saving measures are required by
nations, medical insurers and individuals, and the absolute
savings that could be gained by switching from original
drugs. This paper is designed to discover the degree to
which financial constraints will drive future health spend-
ing, and to discover if legal or safety issues could impact on
any trend in biosimilar use.
The world population growth and population ageing
predict a progressive increase in cancer prevalence [1]. The
World Health Organization (WHO) predicted cancer would
be the world’s leading cause of death by 2010 [2]. While
demographic changes drove up the prevalence of cancer,
cancer research delivered more potential treatments that
patients could use. As a result, the American cancer drugs
budget rose four-fold in the decade 1998 to 2008. Over that
time, cancer medicines became the best-selling class of
drug in the United States, having surpassed lipid regulators
[3]. Many of the new generation of biologic cancer
therapies cost $100,000 per treatment course on an annual
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DOI 10.1007/s11523-011-0196-3basis [4]. This increase in costs may be unsustainable for
even wealthy countries. In the United States, Medicare
costs, which fund care to the over 65-year age group, are
projected to grow at unprecedented levels over the next few
decades, from 11% in 2010 to 24% of all tax revenue by
2030 [5]. In the context of rising demand for medical
treatment and increasing healthcare costs, the development
of “biosimilar” or “biologic follow-on medication” may
provide a route for cost savings.
Methods
A structured literature search was performed for papers and
documents up to 27 August 2011. The Medical Subject
Headings (MeSH) portal of the USA National Library of
Congress’ PubMed database was the primary search portal
[6]. As of 27 August 2011, the term “biosimilar” was not
included [7]. Using the MeSH terms “(”Cost–Benefit
Analysis”[Majr]) AND (“Neoplasms”[Mesh])” revealed
244 publications of which 42 were reviews. Related papers
were identified using the “PubMed” related papers system
and by manual search of references from within these
papers. Web-based documents were searched using the
Google Advanced search engine using the terms “Cost–
Benefit Analysis AND Neoplasms OR cancer.” When a
relevant web page was found, it was searched again for
related content with the Google Related sites program [8].
Data on likely market share by biosimilars was searched
using the Google Advanced search engine using the exact
phrase “market share for biosimilars.” This revealed 31 web
pages up to 13 March 2011. When a relevant web page was
found, it was searched again for related content with the
Google “related sites” program [8]. Where relevant scien-
tific papers were identified or referenced in web pages or
documents, these were located in “PubMed,” and again,
related papers were identified using the”PubMed” related-
papers system and by manual search of references from
within these papers.
Where multiple sources of data were available on a
topic, data from papers and reports by multinational or
national bodies were used in preference to data from
regions or individual hospitals.
Results
The literature search strategy revealed papers and docu-
ments in several grouped themes. The first major theme
was the problem that rising demand for cancer treatment
and cancer treatment costs give to health systems. The
second theme was the current solutions in place to manage
these cost demands. The last theme was the role that
biologic and biosimilar drugs would play in future cancer
medicine.
While there was good agreement between studies on the
first two themes, predictions on the future use of biosimilars
differed between papers from within and outside the US.
The magnitude of the problem—population demographics
The incidence of cancer in people above the age 65 is
nearly 10 times that of people below 65. As the populations
age, health systems and insurers have found themselves
diverting steadily more resources to pay for cancer treat-
ments [9]. Cancer is now the leading cause of death in
many countries. The WHO estimated it had become the
world’s leading cause of death in 2010 [10]. The prediction
of the world cancer burden, projected from population
growth and ageing, suggested 15 million new cases and 10
million new deaths were expected in 2020 [1]. This was
based on a predicted annual rise of 1% in cases and deaths,
with even greater increases expected in China, Russia, and
India. The WHO estimated that new cancer cases would
probably increase to 27 million annually by 2030, with
deaths reaching 17 million each year. For a small,
developed European country such as Ireland, the total
number of new cancers is predicted to almost double in two
decades (1998–2002 and 2020) [11]. In comparison, for
wealthy but developing countries with a young age profile,
such as Saudi Arabia, in two decades the cancer burden is
expected to grow 8 to 10 fold [12].
The magnitude of the problem—financial impact
Cancer medicine is, in many countries, the leading driver of
increased healthcare costs. For example, direct medical
spending for cancer in the USAwas $104 billion in 2010. It
has risen 222% in 20 years, which is faster than any other
branch of medicine in developed countries over the same
era [13]. This threat of growing healthcare costs is not new,
but it impacts increasingly at both a personal and family
level and on national economic policies. Back in 1980, the
US News and World Report magazine wrote that healthcare
costs would rise at an exponential rate, increasing 50-fold
in the 40 years between 1950 and 1990, from $12.75 billion
to $757.9 billion [14]. As a share of the USA GDP, the
national health expenditure has risen from 5.2% in 1960 to
16.2% in 2007 [15]. Over that period, health costs rose
from fifth to first in the family budget [16]. The impact of
this medical advance but financial threat is seen in
increased insurance premiums. In the USA, medical
insurance costs have risen faster than earnings and general
inflation; shown graphically in Fig. 1 [17]. This widening
gap in health spends and earnings will eventually become
unsustainable [18] (Fig. 1).
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threats to the financial solvency of patients [19, 20].
Medical insurance premiums in the USA have more than
doubled since 1999 (131% increase) [21]. A study by the
American Cancer Society found that one in five families
used up all of their savings paying for cancer treatment
[22]. Another showed that 62% of all USA bankruptcies
came from medical expenses [23]. To continue providing
medical care to retired citizens, US Medicare costs are
projected to grow at unprecedented levels over the next few
decades [24]. They are predicted to consume 24% of all tax
revenue by 2030, more than doubling from 11% in 2010.
Using data from the US Centers for Medicare and
Medicaid, the Office of the Actuary and the US National
Health Statistics Group, Sean Keehan points out that the
gap between the large rises in the US National Health
expenditure and smaller rises in national wealth (GDP) will
eventually make healthcare unaffordable [25]. The current
2% gap in rises means that real living standards will fall in
the US, as spending on things other than health is squeezed,
prompting a crisis in health funding within a decade [26].
Cost problems in cancer care are universal. In the
Republic of Korea, life expectancy has risen from 64.8 to
78.5 years in 30 years, to reach the OECD average. Cancer
patients, whose treatment might involve multiple surgical
interventions, chemotherapy and a prolonged period of
hospitalization, may face huge bills as the Korean National
Health Insurance scheme covers only 75% of the cost. The
Republic of Korea has the highest out-of-pocket spending
of any OECD country, with 36% of total health expenditure
coming directly from patient payments at the point of
service in 2007. Inevitably, this results in unaffordable bills
for some. In 2007, an estimated 3% of all households in the
country suffered catastrophic expenditure, defined by the
WHO as an obligatory disbursement greater than or equal
to 40% of residual household income after basic needs have
been met [27].
The magnitude of the problem—cancer drug costs
Cancer is the growth area for novel medicines. Between
July 2005 and December 2007, the US Food and Drugs
Administration (FDA) approved 53 new indications in
oncology, with 18 new molecular entity approvals [28]. The
FDA has also seen a huge increase in investigational agents
studied in cancer, from 925 investigational new drug
applications in 2003 to 1440 in 2008. Innovative drug
development is slow and expensive. From 5000 to 10,000
compounds in pre-clinical trials, only 0.1% reach clinical
trial stage and of these, only 10–20% are finally approved
with a typical development time of 15 years [29]. The high
cost of bringing a novel biologic drug to market has been
estimated at $800 million in 2006. As a result, the
American cancer drugs budget rose four-fold in the decade
1998 to 2008 [3, 30]. During that period, cancer medicines
surpassed lipid regulators to become the best-selling class
of drug.
Ambulatory cancer care seems to be the driver for the
increase in costs. The US Medicare spending on drugs
administered in a doctor’s office, the vast majority of which
are cancer treatments, rose from$3 billion in 1997 to $11
billion in 2004, a 267% increase while overall Medicare
spending rose by only 47% over the same period [31]. The
American data is confirmed in Europe. In France, the
cancer drugs budget has been doubling every 4 years, rising
from €474 million in 2004 to €975 million in 2008 [32].
Most novel cancer drugs are high-cost biologics. These
include imatinib for Chronic Myeloid Leukaemia, trastuzu-
mab for HER2-overexpressing breast cancer, and rituximab
for B-cell lymphomas. All have demonstrated the benefits
of the investment in translational research in basic cancer
science. However, with these advances have come prob-
lems. The principal concern emerges with the cost of
treatment [33]. Because of the innovative but expensive
research and regulation, the cost of novel cancer drugs has
risen by the year of approval [34]. According to a recent
report in the Journal of the National Cancer Institute, 90%
of cancer-fighting drugs or biologics approved by the FDA
over the past 4 years cost more than $20,000 for a 12-week
course of therapy, with many offering a survival benefit of
only 2 months or less [35]. As an example of the effect of
novel drugs on the costs of cancer care, the cost of
treatment using standard chemotherapy regimens evidenced
by randomized trials for metastatic colon cancer was
compared over time [36]. Costs were estimated at 95% of
the average wholesale drug price for May 2004. Using the
Mayo clinic regimen of 5-flurouracil and leucovorin as a
0.0%
25.0%
50.0%
75.0%
100.0%
125.0%
150.0%
175.0%
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
Premiums for Health 
Insurance
Contribution to 
Insurance by 
Workers
Earnings
Overall Inflation in 
USA
Fig. 1 The growth in insurance premiums and employee contribu-
tions to health insurance compared with employee earnings and
general inflation in the USA over time from 1999 to 2010. Data from
the Kaiser/HRET Survey of Employer-Sponsored Health Benefits,
1999-2010. Bureau of Labor Statistics, Consumer Price Index, U.S.
City Average of Annual Inflation (April to April), 1999-2010; Bureau
of Labor Statistics, Seasonally Adjusted Data from the Current
Employment Statistics Survey, 1999-2010 (April to April)
Targ Oncol (2012) 7 (Suppl 1):S57–S67 S59benchmark at $63 for drugs for each 8-week treatment the
costs rose with each improvement. Second-generation
regimens containing irinotecan or oxaliplatin cost $9497
to $11,899 for an 8-week treatment, while third generation
regimens containing bevacizumab or cetuximab cost
$21,339 to $30,790. The rise from $63 to $30,790
represented an almost five hundred-fold rise in drug cost
(30,790/63=488.730159). While some argue that this cost
represents value for the improved outcomes, others point
out that the clinical benefits are not proportionate to the rise
in cost of the drug [37, 38] (Table 1).
The magnitude of the problem—the balance
between increased treatment costs and population
demographics
While novel drug innovation over time may be associated
with reduced cancer death rates, the rising treatment costs
are compounded by demographics [39, 40]. In all societies,
the growth and ageing population is associated with more
cancer to treat. Knowing the relative balance between the
twin drivers of future costs of more cancer patients and
increasingly expensive novel biologic treatments will help
to predict whether cost-containment program can deliver
better healthcare at reduced costs.
The US National Cancer Institute has provided a website
for investigators to review their cancer prevalence and cost
of care projection data [41]. Based on growth and aging of
the US population, medical expenditures for cancer in the
year 2020 are projected to reach at least $158 billion (in
2010)—an increase of 27% over 2010, according to a
National Institutes of Health analysis [42]. Researchers
from the National Cancer Institute (NCI) use this to predict
that if new tests for cancer diagnosis, novel treatment, and
follow-up continue to be more expensive, medical expen-
ditures for cancer could reach as high as $207 billion.
Though increases in the number of beneficiaries account for
some of the increase in the cost of the Medicare program,
new technology is estimated to account for up to 48% of
the change in spending since 1960 [43].
For a developed country, such as the US, the Office of
Management and Budget predicts more costly healthcare per
patient dominates as the driver for rising overall healthcare
costs. In contrast, the aging of the population accounts only
for a modest fraction of the projected growth in federal
spending on Medicare and Medicaid. This is shown graph-
ically in Fig. 2. This is useful information, as it gives hope
that cost-control programs can contribute to affordable future
health care as there would be little that could be done in the
face of unchangeable demographics (Fig. 2).
The magnitude of the problem—interventions
that could be implemented at a national level
Oncologists have a duty of care to future as well as current
patients. We are reminded by the WHO “to require the
health system to obtain the greatest possible level of health
from the resources devoted to it.” This is “to ask that it be
as cost-effective as it can be” [44]. Concentration on cost
alone is not enough. Simplistic economic assessments
concentrate on limiting access to high-cost treatments by
rationing. This, however, misses the point that many cheap
but common high-volume treatments may be relatively
ineffective, whereas some expensive novel medicines are
highly effective and save money elsewhere in the health
system; by increasing cures or by saving money from other
healthcare budgets. For example, trastuzumab (a monoclo-
nal antibody) costs about $70,000 for a full course of breast
cancer adjuvant treatment and is associated with a 52%
reduction in disease recurrence and 33% reduction in death
[45, 46]. Over a lifetime, the cost for each extra quality
adjusted life year (QALY) is estimated at $27,800 (range
$18,000–39,000) [47]. In contrast, extending the hospital
stay of myocardial infarction patients beyond 4 days costs
$105,000 per QALY gained [48].
Physicians need to be reassured that economics is not
primarily about saving money. It is about using scarce
resources as efficiently as possible. Economists never say
“cheap” or “expensive”—they say “cost-effective” or “not
cost effective.” Since rationing occurs in every health
system, either by personal ability to pay or by society’s
willingness to pay it, physicians need to understand how
economic studies can contribute to improved patient well
being and health. To understand the cost-effectiveness of
treatments, we need to know both costs and effects. Costs
to consider are of treating, of not treating, and of alternate
treatments. Effects include the benefits seen, their magni-
tude and duration. Balanced against them are the treatment
Table 1 The costs of treating metastatic colon cancer compared by drug treatment era. Data adapted from Schrag D. NEJM. 2004;351:317–319
Treatment era Drug regimens Range of cost for 8 weeks treatment
in US Dollars (at 2004 equivalents)
1
st generation Mayo clinic regimen of 5-flurouracil and leucovorin $63
2
nd generation Regimens containing irinotecan or oxaliplatin $9,497 to $11,899
3
rd generation Regimens containing biologic drugs: bevacizumab or cetuximab $21,339 to $30,790
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effectiveness study, the balance requires single metric of
costs and a single metric of risks/benefits to the length and
quality of life. In practice, this has now become the
incremental cost effectiveness ratio (ICER). This is the
monetary cost required to gain an extra Quality Adjusted
Life Year (QALY) from each treatment [49, 50]. The
derivation of a QALY is shown graphically in Fig. 3.A sa n
example of QALY calculations, an intervention that
lengthened life for a whole year at 100% full quality of
life (QOL) would have gained 1 QALY (1×1=1 QALY).
Another intervention that gained 6 months extra life lived at
50% of normal full QOL would have gained only 0.25 of a
QALY (0.5×0.5=0.25 QALY). Another that gained 2 extra
years at 75% of full QOL would have gained 1.5 QALY
(2×0.75=1.5) (Fig. 3).
While it may appear initially cruel to set a threshold
ICER above which new treatments are not approved or
reimbursed, policy makers will generally have aims that
physicians would support. The policy aims to protect and
improve the health of the population, to assure access to
medical care, to achieve efficient use of healthcare
resources, and thus control the rate of growth of expendi-
tures for medical care to ensure that a sudden funding crisis
does not occur, which threatens the basic medical provi-
sion. The World Health Report for 2000 makes it clear that
money itself does not buy health or longevity [51]. To
achieve life expectancy between 78 and 82 years, the 191
WHO member states spend between $2000 and $6000 per
capita on health. In this range, there is only a weak
correlation between spend and longevity. When freedom
from disability was studied, the range of spend varied more
than ten-fold.
It becomes increasingly important that when a treatment
has a low cost effectiveness, physicians should ask is it
worth doing compared to other things we could do with the
same money? Assuming we worry about costs, and that
some publicly funded healthcare is essential, it is reason-
able to ask could we perform better? In the US, there are
185 publicly funded interventions which together cost
about $21.4 billion per year, for an estimated saving of
592,000 years of life (considering only premature deaths
prevented). The power of rational spending on health to
maximise gain is shown from a study of re-allocating those
funds to the most cost-effective interventions. The change
could double the benefit and save an additional 638,000 life
years for the same spend [52].
It is for this reason that many countries set a threshold
Incremental Cost Effectiveness Ratio (ICER) above which
they are unlikely to recommend reimbursement [53]. While
the best-known institution for managing these assessments
may be the United Kingdom National Institute for health
and Clinical Excellence (NICE), there are similar systems
with budget impact or formal cost-effectiveness approval
for novel treatments in many countries. By 1999, economic
assessments of novel treatments were routine in the UK,
Australia, Belgium, Canada, Denmark, Finland, German,
Hungary, the Netherlands, Norway, Portugal, and Sweden
and more have followed the fist wave in subsequent years
[54, 55]. Of three OECD English-speaking countries, the
UK, the USA and Canada, it is instructive to see in Fig. 4
that a focus on formal cost-effectiveness approval is
associated with a slower rise in healthcare costs from1960
to 2008, and that in Table 2, that life expectancy is not
proportional to health spending. At the same time, cancer
death rates continue to fall in each country [56–59] (Fig. 4,
Table 2).
The WHO has suggested that countries might decide on
a threshold at a multiple of the nations’ wealth, measured
Fig. 3 A diagram to represent the QALY effect. Treatment A
increases length and quality of life over control. Treatment B increases
only quality of life over treatment A. Treatment B is clinically better
than treatment A (it gains more QALYs than treatment B) but the
ICERs of the two different interventions are required to decide which
is the most cost-effective option?
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Fig. 2 The relative effect of demographics and increased unit
treatment costs on the spending on Medicare, Medicaid as a% of
USA over time from 2007 to 2082. The aging of the population
accounts only for a modest fraction of the projected growth in federal
spending on Medicare and Medicaid, while costs increasing at current
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three times GDP have been proposed above which the
resource could probably be spent better to save more lives
or disability, and funding could be withheld [60]. In
practice, health economic institutions seem unwilling to
publish absolute ICER threshold limits, but by studying the
patterns or approval or by reading discussion papers, a
range of ICER levels can be established [46]. The UK
NICE ICER threshold appears to be £30,000/QALY for
general health and up to £45,000/QALY in the terminal
phase of illness. The Netherlands has proposed €50,000–
80,000/QALY for curative treatment. Sweden has levels at
about 500,000 SEK/QALY. The range then seems to lie for
these countries in the $45,000 to $110,000 equivalent
range; or approximately two to three times per capita GDP
which is in line with the WHO guidance.
While much critical publicity surrounds negative reim-
bursement decisions by the UK NICE, it is instructive to
see how this might impact cancer patients and their
physicians. Up to August 2008, NICE had approved 97%
of treatments [61]. Only 3% were rejected outright while
25% were approved only for restricted subsets of patients in
whom there was a higher probability of benefit and 72%
were fully approved. Of 11 cancer drugs rejected for
reimbursement by NICE, only 3 of 11 had proven overall
survival benefit. The absolute benefit for the three were 1.8,
3.6, 4.7 months for an ICER of between 47,000 and
94,000 lb/QALY (70,000 and 141,000 dollars/QALY). Of
the 9 of 11 drugs rejected with no proven survival
advantage, the ICER ranged from >€30,000–171,000/
QALY (>$45,000–257,000/QALY) [62]. Examples of
recent positive NICE approvals include cetuximab for
colorectal cancer with an ICER between £26,700 and
£33,300, and Rituximab for Chronic Lymphatic Leukaemia
at probably less than £30,000.
The near universal acceptance of cost/QALY assessments
for new medicines has delivered a clear mechanism for cost
control to most health systems. However wealthy the country
maybe,newtreatmentswillbe judgedonthecost-effectiveness
of the intervention. This is likely to be the greatest driver for the
choice of health investment in the short and medium term in
countries and health systems that wish to manage costs.
The magnitude of the problem—interventions
that can be implemented at a local or individual
physician level
Faced with the twin threats of demographics and rising
treatment costs, there is now a duty for oncologists to be
economically literate as well as compassionate and medi-
cally competent [63]. While many of the intrinsic problems
of drug pricing and health prevention measures seem
beyond the reach of individual physicians or hospitals to
influence, there are practical things that can still be done
which are actively promoted to physicians.
Individual physicians or hospitals can improve cost
effectiveness with a program of evidence-based medicine
[64–67]. For example, it has been estimated that about 30%
of the total annual US expenditure on healthcare is spent on
ineffective or redundant care [68].
Doctors may find it difficult to discuss money issues in
clinic with patients and their families [69]. Furthermore, we
are uncertain how a patient faced with a cancer diagnosis
will receive and use any information on costs [70]. Despite
these difficulties, the attitude of doctors to the problem of
costs is changing. In 2006, a survey of Massachusetts’s
oncologists shows that 88% of oncologists thought that cost
should not impact their treatment decisions at all [71].
However, by 2008, opinions were changing. When asked
“has your consideration of drug costs in clinical decision
making changed from a year ago?” 57% reported they
considered costs more and only 3% less [72].
With the help of local pharmacists, individual physicians
or hospitals can save on costs of established treatment
programs with a policy of bulk buying with negotiated
discounts and generic substitutions [73]. Bulk discounts of
more than 50% over the list price are recorded in the UK
[74]. Generic substitution offers further cost-effective
savings for individuals, hospitals, and health plans to
Fig. 4 Expenditure on health in US Dollar purchasing power parity
equivalents over time for 3 English-speaking countries. The UK and
Canada have explicit rationing of health expenditure for novel
treatments while the USA does not. Data from http://www.oecd.org/
document/16/0,3746,en_2649_37407_2085200_1_1_1_37407,00.
html. Accessed 6 March 2011
Table 2 Life expectancy for men and women in 3 English-speaking
countries in 2007. Data from OECD. Available at http://www.oecd.
org/document/16/0,3746,en_2649_37407_2085200_1_1_1_37407,00.
html. Accessed 6 March 2011
Male Female
UK 77.6 83
Canada 78.0 81.8
USA 75.3 80.4
S62 Targ Oncol (2012) 7 (Suppl 1):S57–S67exploit. The US Congressional Budget Office (CBO)
looked at potential drug savings in Medicare Part D, which
provides outpatient prescription drug benefits for senior
citizens and people with disabilities. They found that the
use of generic medications rather than brand-name medi-
cations saved beneficiaries and the program about $33
billion in 2007 [75]. They predicted an additional $14
billion in savings is expected as first-time generics entered
the market in 2012.
In the US, each 1% increase in generic prescribing
reduces drug costs by $1.32 billion annually [76]. Generic
substitution is highly cost effective. In the UK, the average
cost of a generic is a quarter of the original brand (£4.83
and £19.33 respectively) [77]. While generic substitution is
one area where individual physicians and hospitals could
impact quickly and significantly on the cost-effectiveness
of cancer care, there is a significant variation in the
practice. Only 4 of 22 countries in the EU manage to
prescribe generics in two-thirds or more of prescriptions by
volume [78]. To demonstrate the magnitude of cost savings
that could be realized, the generic substitution of just the
top 10 prescribed drugs in different EU countries could
release savings of 21 to 48% to reinvest in improved patient
care. Savings of 40-50% of the budget were predicted for
Denmark, Germany, Portugal, Belgium and the Netherlands;
of30–40%inFrance,Spain,theUKandItaly;andof20–30%
in Austria and Poland.
While for many, the practice of “grey importing” of
pharmaceuticals from another country seems of dubious
merit, this has the potential for significant savings and is
practiced widely. At present, to secure a stable price for
forward planning and supply, pharmaceutical companies
sell drugs at different negotiated prices in different
countries. A London School of Economics study by Panos
Kanavos estimates that with an open EU markets for
generics, significant savings would follow. For a country
that spends about 15 billion euros on medicines, and about
5 or 6 billion euros of that on generics, it could save about a
quarter of that, simply because they could be paying too
much. This implies savings of 1 to 1.5 billion euros, up to
10% of the entire drug budget [79].
Generic substitution is not possible with biologic drugs.
This is important for each hospital to consider; however, as
biological therapies are a key driver of increased cancer
costs. Not only is the use of biologics growing at twice the
rate of prescription drugs, but also their costs are
significantly higher than conventional small molecule
agents [80]. In the US alone, for 2010, it has been
estimated that biologic drug sales would exceed $60 billion
[81].
With the help of local pharmacists, individual physicians
or hospitals can save on costs of established treatment
programs with a policy of biologic drug equivalent
substitutions. For biologic drugs, there is a new class of
“biosimilar” or “follow-on biologic” drugs available to
replace biologic drugs that have expired their patents. The
first of this novel class of drug was somatrophin, licensed
by the EMEA in 2006. As with all recombinant products,
the tertiary structure and activity of these drugs can be
altered by different growth conditions and media. All
biologic drugs show some batch-to-batch variation, whether
originator or biosimilar [82, 83].
A study in Nature Biotechnology in 2011 sampled three
different originator biologic drugs over 2007–2011 and
showed that all three drugs had detectable changes in some
aspect of tertiary structures over that period when samples
with different expiry dates were tested [82]. It is clear
therefore that all biologic drugs may to some extent be a
“biosimilar” of their original culture and preparation
techniques. The degree of acceptable variation that does
not change the clinical effects of the biologic drug is
however the subject of great debate. This is one reason why
the pathway to approval of biosimilar drugs is much more
complex and prolonged that for small molecule generic
drugs. This also explains why the EMEA biosimilar
registration pathway, to date, has required a clinical trial
with some demonstration of comparative clinical effective-
ness of the “biosimilar” compared to the originator drug
[83].
Biologic equivalent drugs are a challenge to make as
variations in manufacturing steps of culture, extraction and
purification can alter dimerisation, deamidation, oxidation
and glycosylation patterns and the tertiary protein structure,
and thus drug activity and toxicity. This was demonstrated
in practice when an originator recombinant epoetin alfa
production line was moved from the US to Europe, and
immunogenicity of the new version provoked an increase in
pure red cell aplasia [84]. Pure red cell aplasia is a clinical
problem for the whole class of epoetin drugs when given
long term for the anaemia of chronic renal failure, but a
significant rise in cases was detected. As a consequence, by
2008, fifteen countries have banned automatic substitution
of biosimilars [85].
Biosimilar is a regulatory term created by the European
Medicines Agency (EMEA), to denote a tested and
regulated drug with the same expected sequence, safety
and activity as the originator reference drug [86]. In the US
the term is “biologic follow-on drug” to denote such drugs
regulated and licensed by the US Food and Drugs
administration (FDA). These share the same DNA sequence
as the originator product, and have to demonstrate
equivalent activity and toxicity before approval with
clinical trials and agreed post-marketing surveillance. The
EMEA explicitly recognizes that existing biosimilars can
and should have the same International Non-Proprietary
Name (INN) as their reference product.
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simple unregulated and unlicensed copy biologic drugs that
have been produced prior to patent expiry and marketed
outside the EU and North America. The EMEA requires
significantly more testing for biosimilars than for small
molecule generics, including clinical trials and a formal
post-marketing surveillance program before approval.
In Asia, the term “biogeneric” has been used to describe
unregulated and unlicensed copy biologic drugs that have
been produced prior to patent expiry. A recent review from
India, reported more than 50 brands now on sale and that
price becomes the key marketing force [87]. Biogeneric
copy drugs appear within 2 to 3 years of market launch,
forcing down prices for both biogeneric producers and
innovator companies. This price-sensitivity has led to
companies cutting quality controls with the result that
significant differences in comparability with the innovator
drug are found, which lead to very different dose and
activity profiles.
In contrast to EMEA-regulated biosimilars, unregulated
biogeneric copy drugs of biologics may share the same
DNA sequence, but have potentially significant variations
in post-translation chemistry; seen as novel isoforms of the
drugs with altered glycosylation patterns and significantly
altered activity [88]. Many will never have had formal
clinical testing. Within the EU however, a novel regulatory
pathway and licensing system has been introduced to
ensure that biosimilars behave in the same way as
originator drugs [89]. Confusion about the difference
between unregulated copy biologics and regulated biosimi-
lar or biologic follow-on equivalent drugs will need to be
clarified for oncologists to be confident to initiate a
program of biosimilar equivalent substitution in their own
practice [85].
For 2011, the EU has only a limited range of biosimilar
drug classes approved for oncology. To date these are all
supportive care cancer hormonal agents; biosimilar eryth-
ropoetins and biosimilar filgastrim G-CSF. With EU patent
time expiry, however, this will soon include the more
structurally complex monoclonal antibody (mAb) therapies
such as imatinib for CML, trastuzumab for HER2- over-
expressing breast cancer, and rituximab for B-cell lympho-
ma. The market for these therapies is estimated at $36.4 to
$40 billion [90, 91]. In preparation for those, the EMEA
released draft guidelines for their biosimilar development in
November 2011. Estimated by patent expiry dates, oncol-
ogy antibody products will appear in 2015, followed by
darbepoetin biosimilars in 2016 [92].
To succeed, biosimilar drugs will need to be cheaper
than their original reference drugs. In the UK, the Scottish
National Health Service has published data on the cost
saving from buying biosimilar G-CSF. Based on its use in
myelotoxic breast cancer chemotherapy, the estimated
savings over a 12-week schedule was more than £300 per
patient.
Annual savings of €1.6 billion per year have been
predicted if the European Union could realize a 20% price
reduction of just five patent expired biopharmaceuticals
[93]. Predictions are that cost savings of 25 to 30% can be
achieved [94]. Looking forward further to 2020, there are
20 biologic drugs in the EU which will come off patent that
generate more than $300 million in revenue in Europe
alone [95]. Such savings will be hard to resist in such a
regulated EU health market. If biosimilar drugs escape
immunogenicity and safety scares, then they are likely to
become closely equated to “generics” for small molecule
medicines. Few oncologists are likely to be able to name
the producers of the major off-patent cytotoxic drugs at
their hospitals and clinics. Even less will have ever been
involved in their selection and purchase. With the pressure
for cost control, it seems inevitable that they will come
under automatic promotion by the health technology
appraisal systems common in European health systems
such as NICE. With such promotion, the global use of
biosimilars is predicted to follow a compound annual
growth rate of 65.8% per year [96].
The country that has set the benchmark for early
adoption of biosimilars in Europe is Germany. Even in
early 2008, the half of epoetin (55%) and a third of GCSF
(31%) prescriptions were biosimilars [97]. The effect of
price competition on biologic drug use was also illustrated
by epoetin in Germany. Three biosimilars were introduced
in 2008 with a 30% below the originator price. A price
reduction by the originator was followed by further price
reductions by the biosimilars and then again by one of the
originators [98].
The contrast between the EU and the US is in the speed
and clarity of the legal development of regulator pathways
for biosimilar drug development. The issue appears to be
politicized in the USA where the “Biologics Price Compe-
tition and Innovation Act” is in discussion. In recent US
government debates, Time magazine suggested that in the
first six months of 2009 alone, drug and biotech companies
and their trade associations spent more than $110 million
lobbying to influence decisions with more than 2 lobbyists
for every member of Congress [99]. Once an effective
American legal pathway to biosimilar introduction is
present, sales are also likely to rise rapidly. This is predicted
by the high price of originator biologics and patient
pressure because so many patients have to pay significant
parts of medical bills through co-insurance fees. This is
seen already in the American generic market, where such
drugs account for more than 50% of the total US
prescriptions [100]. For the US, patents have already
expired on biologic drugs representing more than $15
billion in costs annually [101]. Even with modest price
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$4.5 billion that will be impossible for health insurers and
hospitals to resist. A 2008 analysis by Robert Shapiro
suggested that generic versions of the top 12 categories of
biologics whose patents have expired or will expire soon
could save Americans up to $108 billion in the first
10 years and as much as $378 billion over two decades.
The impression that a biosimilar-regulated USA will
embrace biosimilars quickly is supported by predictions
that biosimilar epoetin market gain is likely to be more
rapid and more complete in the United States compared to
biosimilar erosion seen in Europe [102]. More than half of
surveyed US physicians reported that they would begin
prescribing a biosimilar epoetin within 6 months of its
launch and 88% expect to be using it within a year. In
contrast, the majority of surveyed German nephrologists
did not begin using biosimilar epoetin until the drugs had
been on the market for 13–24 months. Uptake of
biosimilars among surveyed French nephrologists has been
even more conservative—60% of surveyed physicians
report they still do not prescribe biosimilar epoetin [103].
Conclusions
Without intervention, even wealthy countries face a crisis in
healthcare spending, driven principally by novel high-cost
biologic cancer drug development and to a lesser extent by
demographics. This places a responsibility upon oncologists
to become more economically literate, with the confidence to
read and react to new cost-effectiveness studies.
While individual hospitals and physicians may seem
powerless to make a difference, a local program of
evidence-based medicine, generic, and biosimilar substitu-
tion could help ensure healthcare costs remain sustainable.
Biosimilar drug substitution offers the latest way for
oncologists to save costs for reinvestment. However, as
biosimilar medicines represent a whole new class of
medicines, this step will be more complex than generic
substitution. It may require a significant program of
education and partnership between pharmacists, physicians,
and patients to be realized fully.
For centralized healthcare systems, and those with a
strong tradition of generic medicine use, biosimilar use will
clearly rise with predictions of more than 80% of
prescriptions of some biologic drugs within 1 year of
market entry in the USA. Delaying the implementation of
such programs, however, risks a real crisis in healthcare
delivery for many countries and hospitals that few can now
afford.
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